Dr David Steensma  
Associate Professor,  
Medicine Harvard Medical School  
Faculty member,  
Adult Leukemia Program  
Dana-Farber Cancer Institute, Boston

“Emerging Evidence in MDS”

Wednesday, October 28, 2015
GLEN Site – Room D02.1312
8:30 to 9:30

Hôpital Maisonneuve-Rosemont - Room 080
12:00 to 13:00

Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00
Live on the Web!  
www.vpsolution.tv/vspo
Problems/Questions:  
514 813-4510

Thursday, October 29, 2015
Jewish General Hospital – Room E-7
12:30 to 13:30

Learning objectives
• To discuss innovative and emerging approaches to the current management of MDS patients (treatment choice, dose and schedule considerations, outlook and management of patients relapsed or refractory to hypomethylating agents, prospects for combination therapies)
• To provide insight into genetic testing in cases of suspected MDS including the frequency of mutations, the prognostic value of mutations and the utility of genetic testing in therapeutic decision making
• To provide clinicians with insight into the future landscape for the management of MDS patients

“Practical Case Based Discussion of the Management of MDS”

Thursday, October 29, 2015
Hôpital du Sacré-Cœur de Montréal
Room G-4115
15:00 to 16:00

Learning objectives
• To provide clinicians with an overview of the current therapeutic options for treating MDS (lower and higher risk)
• To provide clinicians with practical guidance through case based discussion of the optimal utilization of current therapeutic options (choosing the appropriate patients, managing comorbidities and early cycle adverse events, optimizing the duration of treatment)
• To provide clinicians with insight into the future landscape for the management of MDS patients

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp